iron sucrose + erythropoietin (American Regent, Inc.)

This combination therapy regimen consists of intravenous iron sucrose and recombinant erythropoietin (typically epoetin alfa), used primarily for the treatment of anemia in patients with chronic kidney disease (CKD), including those not on dialysis. Iron sucrose is an intravenous iron replacement product that provides elemental iron for hemoglobin synthesis, addressing iron deficiency. Erythropoietin is a recombinant glycoprotein hormone that acts as an erythropoiesis-stimulating agent (ESA) by binding to erythropoietin receptors on red blood cell precursors in the bone marrow, stimulating their proliferation and differentiation. American Regent, Inc. (the U.S. marketer of Venofer) has been involved in clinical research evaluating the efficacy of this combination compared to oral iron supplements in managing renal anemia. This dual approach is designed to optimize red blood cell production by providing both the hormonal stimulus and the necessary iron substrate.

Brand names

Venofer

Other names

iron sucrose + epoetin alfaVenofer + erythropoietinIV iron sucrose plus erythropoietin